Skip to main content
Top
Published in: BMC Urology 1/2020

Open Access 01-12-2020 | Prostate Cancer | Research article

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml

Authors: Tsung-Hsin Chang, Wun-Rong Lin, Wei-Kung Tsai, Pai-Kai Chiang, Marcelo Chen, Jen-Shu Tseng, Allen W. Chiu

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

The current study aimed to compare the efficacy of transition zone PSA density (TZPSAD) with traditional PSA and PSA density (PSAD), for the diagnosis of prostate cancer (PCa) in Taiwanese males.

Methods

Men with PSA between 4.0 and 20.0 ng/ml who underwent a transrectal ultrasound (TRUS) guided prostate biopsy between the studied period were retrospectively identified. The demographic data, PSAD and TZPSAD were calculated in all patients. Receiver operating characteristic (ROC) curves were used to analyze the accuracy of a positive PCa diagnosis.

Results

The area under the ROC (AUC) was 0.615, 0.748 and 0.746 for PSA, PSAD and TZPSAD, respectively. The best cut-off of value for TZPSAD in predicting PCa in men with a PSA of 4.0–10.0 ng/ml was 0.367 ng/ml/ml with a sensitivity of 50% and a specificity of 77.5%. In men with a PSA of 10.1–20.0 ng/ml, the best cut-off value was 0.454 ng/ml, with a sensitivity of 74.8% and specificity of 70.9%.

Conclusion

The use of TZPSAD can improve the efficiency and specificity of PSA for the diagnosis of PCa in Taiwanese men with PSA 4.0–20.0 ng/ml. TZPSAD efficiency was similar to PSAD but TZPSAD had better cancer specificity.
Literature
1.
go back to reference Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. CrossRef Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. CrossRef
2.
go back to reference Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. CrossRef Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. CrossRef
3.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. CrossRef Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. CrossRef
4.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. CrossRef
5.
go back to reference Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9. CrossRef Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9. CrossRef
6.
go back to reference Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16. CrossRef Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16. CrossRef
7.
go back to reference Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147(3 Pt 2):817–21. CrossRef Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147(3 Pt 2):817–21. CrossRef
8.
go back to reference Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43(5):601–6. CrossRef Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43(5):601–6. CrossRef
9.
go back to reference Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–31. CrossRef Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–31. CrossRef
10.
go back to reference Tang P, Du W, Xie K, Deng X, Fu J, Chen H, Yang W. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. Urol Oncol. 2013;31(6):744–8. CrossRef Tang P, Du W, Xie K, Deng X, Fu J, Chen H, Yang W. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. Urol Oncol. 2013;31(6):744–8. CrossRef
11.
go back to reference Fujinami K, Miura T, Takizawa A, Osada Y, Kawakami S. Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1–10 ng/ml]. Nihon Hinyokika Gakkai zasshi. Jpn J Urol. 2005;96(4):475–9. CrossRef Fujinami K, Miura T, Takizawa A, Osada Y, Kawakami S. Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1–10 ng/ml]. Nihon Hinyokika Gakkai zasshi. Jpn J Urol. 2005;96(4):475–9. CrossRef
12.
go back to reference Nowroozi M, Ayati M, Jamshidian H, Arbab A, Ghorbani H, Amini E, Hakima H, Salehi S, Ghadian A. Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men. Nephro-Urol Mon. 2015;7(2):e26752. CrossRef Nowroozi M, Ayati M, Jamshidian H, Arbab A, Ghorbani H, Amini E, Hakima H, Salehi S, Ghadian A. Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men. Nephro-Urol Mon. 2015;7(2):e26752. CrossRef
13.
go back to reference Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83. CrossRef Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83. CrossRef
14.
go back to reference Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol. 2001;165(2):445–54. CrossRef Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol. 2001;165(2):445–54. CrossRef
15.
go back to reference Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914–31. CrossRef Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914–31. CrossRef
16.
go back to reference McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906. CrossRef McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906. CrossRef
17.
go back to reference Kurita Y, Ushiyama T, Suzuki K, Fujita K, Kawabe K. PSA value adjusted for the transition zone volume in the diagnosis of prostate cancer. Int J Urol. 1996;3(5):367–72. CrossRef Kurita Y, Ushiyama T, Suzuki K, Fujita K, Kawabe K. PSA value adjusted for the transition zone volume in the diagnosis of prostate cancer. Int J Urol. 1996;3(5):367–72. CrossRef
18.
go back to reference Amini E, Pishgar F, Ayati M, Jamshidian H, Arbab A, Gooshe M, Nowroozi MR. Transition zone prostate-specific antigen density could better guide the rebiopsy strategy in men with prostate inflammation at initial biopsy. Urology. 2015;86(5):985–90. CrossRef Amini E, Pishgar F, Ayati M, Jamshidian H, Arbab A, Gooshe M, Nowroozi MR. Transition zone prostate-specific antigen density could better guide the rebiopsy strategy in men with prostate inflammation at initial biopsy. Urology. 2015;86(5):985–90. CrossRef
19.
go back to reference Sung DJ, Cho SB, Kim YH, Oh YW, Lee NJ, Kim JH, Chung KB, Moon DG. Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography. J Ultrasound Med. 2004;23(5):615–22. CrossRef Sung DJ, Cho SB, Kim YH, Oh YW, Lee NJ, Kim JH, Chung KB, Moon DG. Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography. J Ultrasound Med. 2004;23(5):615–22. CrossRef
20.
go back to reference Wang Y, Xie S, Shangguan X, Pan J, Zhu Y, Xin Z, Xu F, Shao X, Fan L, Sha J, et al. Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J Cancer Res Clin Oncol. 2017;143(7):1157–66. CrossRef Wang Y, Xie S, Shangguan X, Pan J, Zhu Y, Xin Z, Xu F, Shao X, Fan L, Sha J, et al. Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J Cancer Res Clin Oncol. 2017;143(7):1157–66. CrossRef
21.
go back to reference Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 1998;160(2):411–8 ((discussion 418-419)). CrossRef Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 1998;160(2):411–8 ((discussion 418-419)). CrossRef
22.
go back to reference Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Ann Clin Lab Sci. 2003;33(3):320–3. PubMed Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Ann Clin Lab Sci. 2003;33(3):320–3. PubMed
23.
go back to reference Elliott CS, Shinghal R, Presti JC Jr. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. J Urol. 2008;179(5):1756–61 ((discussion 1761)). CrossRef Elliott CS, Shinghal R, Presti JC Jr. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. J Urol. 2008;179(5):1756–61 ((discussion 1761)). CrossRef
Metadata
Title
Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
Authors
Tsung-Hsin Chang
Wun-Rong Lin
Wei-Kung Tsai
Pai-Kai Chiang
Marcelo Chen
Jen-Shu Tseng
Allen W. Chiu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00717-z

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue